Protein Recognition of Gold-Based Drugs: 3D Structure of the Complex Formed When Lysozyme Reacts with Aubipy(c)(628 views) Messori L, Cinellu MA, Merlino A
Acs Med Chem Lett (ISSN: 1948-5875, 1948-5875linking), 2014 Jul 31; 5(10): 1110-1113.
Keywords: Gold-Based Drugs, Metallodrugs, Protein-Ligand Interactions, Antineoplastic Agent, Egg White, Glutamine, Lysozyme, Organogold Compound, Prodrug, Article, Complex Formation, Crystal Structure, Drug Protein Binding, Molecular Recognition, Reduction, X Ray Crystallography, X Ray Diffraction,
Affiliations: *** IBB - CNR ***
Department of Chemistry, University of Florence, Via della Lastruccia, 3-13Florence, Italy
CNR Institute of Biostructure and Bioimages, via Mezzocannone 16Napoli, Italy
References: Not available.
Protein Recognition of Gold-Based Drugs: 3D Structure of the Complex Formed When Lysozyme Reacts with Aubipy(c)
The structure of the adduct formed in the reaction between Aubipy(c), a cytotoxic organogold(III) compound, and the model protein hen egg white lysozyme (HEWL) has been solved by X-ray crystallography. It emerges that Aubipyc, after interaction with HEWL, undergoes reduction of the gold(III) center followed by detaching of the cyclometalated ligand; the resulting naked gold(I) ion is found bound to the protein at G1n121. A direct comparison between the present structure and those previously solved for the lysozyme adducts with other gold(III) compounds demonstrates that coordinated ligands play a key role in the protein metallodrug recognition process. Structural data support the view that gold(III)-based antitumor prodrugs are activated through metal reduction.
Protein Recognition of Gold-Based Drugs: 3D Structure of the Complex Formed When Lysozyme Reacts with Aubipy(c)
No results.
Protein Recognition of Gold-Based Drugs: 3D Structure of the Complex Formed When Lysozyme Reacts with Aubipy(c)
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(638 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote